These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

50 related articles for article (PubMed ID: 2620116)

  • 1. [Comparison of the pharmacokinetics of cisplatin administered by the intraperitoneal route in 2 dosages: 100 and 200 mg/m2].
    Canal P; Chatelut E; De Forni M; Chevreau C; Johnson N; Houin G; Bugat R
    Bull Cancer; 1989; 76(8):879-82. PubMed ID: 2620116
    [No Abstract]   [Full Text] [Related]  

  • 2. [Phase I trial and pharmacokinetics of VM 26 combined with cisplatin administered by the intraperitoneal route without mixing time].
    Chatelut E; Canal P; De Forni M; Chevreau C; Houin G; Bugat R
    Bull Cancer; 1989; 76(8):893-6. PubMed ID: 2620120
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparison of the intraperitoneal and intravenous routes of cisplatin administration in an advanced ovarian cancer model of the rat.
    Sekiya S; Iwasawa H; Takamizawa H
    Am J Obstet Gynecol; 1985 Sep; 153(1):106-11. PubMed ID: 4041136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacokinetics study of intraperitoneal cisplatin in ovarian carcinoma].
    Han GR; Cai GF
    Zhonghua Fu Chan Ke Za Zhi; 1993 Apr; 28(4):224-6, 254. PubMed ID: 8404307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ip cisplatin in patients with malignant ascites: pharmacokinetic evaluation and comparison with the iv route.
    Casper ES; Kelsen DP; Alcock NW; Lewis JL
    Cancer Treat Rep; 1983 Mar; 67(3):235-8. PubMed ID: 6682012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Concentration of cis-platinum in portal blood and peripheral blood after intraperitoneal administration].
    Sato Y; Ohtsuka K; Ono K; Kawakami S; Furutani S; Tsuji H; Yamada M; Ikeda E
    Gan To Kagaku Ryoho; 1994 Mar; 21(4):551-3. PubMed ID: 8129399
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical pharmacokinetics of cumulative very high dose of cisplatin in chemotherapy resistant solid tumors.
    Tebano MT; Carlini P; Loizzo A; Luzi M; Petrucci F; Alimonti A; Caroli S
    Ann Ist Super Sanita; 1995; 31(3):351-7. PubMed ID: 8712579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and pharmacodynamics of cisplatin after intraoperative hyperthermic intraperitoneal chemoperfusion (HIPEC).
    Zeamari S; Floot B; van der Vange N; Stewart FA
    Anticancer Res; 2003; 23(2B):1643-8. PubMed ID: 12820435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical trials with intraperitoneal cisplatin microspheres for malignant ascites--a pilot study.
    Hagiwara A; Takahashi T; Sawai K; Sakakura C; Tsujimoto H; Osaki K; Sakakibara T; Ohyama T; Ohgaki M; Muranishi S
    Anticancer Drug Des; 1993 Dec; 8(6):463-70. PubMed ID: 8286013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intraperitoneal administration of cisplatin and etoposide during surgery for patients with gastric cancer.
    Tsujitani S; Watanabe A; Abe Y; Maehara Y; Sugimachi K; Kaibara N
    Anticancer Res; 1993; 13(6B):2497-9. PubMed ID: 8135489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Studies on the appropriate administration of cisplatin based on pharmacokinetics and toxicity].
    Kitajima K; Fukuoka M; Kobayashi S; Kusunoki Y; Takada M; Negoro S; Matsui K; Sakai N; Ryu S; Takifuji N
    Gan To Kagaku Ryoho; 1987 Aug; 14(8):2517-23. PubMed ID: 3039920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effects of adjuvant hyaluronidase in tumors refractory to chemotherapy. Review of the literature and pharmacokinetics of cisplatin after regional administration in animals and humans].
    Civalleri D; Esposito M; De Cian F; Balletto N; Vannozzi MO; Mondini G; Carrabetta S; Bocchio MM
    G Chir; 1997 Apr; 18(4):175-81. PubMed ID: 9303630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose biweekly intraperitoneal cisplatin: an effective way to increase cisplatin dose intensity.
    Bonetti A; Howell SB; McClay E; Kirmani S; Goel R; Plaxe S; Braly P; Kim S
    Gynecol Oncol; 1993 Jun; 49(3):318-24. PubMed ID: 8314533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and adverse reactions of a new liposomal cisplatin (Lipoplatin): phase I study.
    Stathopoulos GP; Boulikas T; Vougiouka M; Deliconstantinos G; Rigatos S; Darli E; Viliotou V; Stathopoulos JG
    Oncol Rep; 2005 Apr; 13(4):589-95. PubMed ID: 15756428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacokinetic study of intraperitoneal chemotherapy with high-dose cisplatin for advanced ovarian cancer].
    Deng C; Huang R; Lian L
    Zhonghua Fu Chan Ke Za Zhi; 1996 Mar; 31(3):159-62. PubMed ID: 8758790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Feasibility of using intraperitoneal epinephrine and cisplatin in patients with advanced peritoneal carcinomatosis.
    Molucon-Chabrot C; Isambert N; Benoit L; Zanetta S; Fraisse J; Guilland JC; Royer B; Monin-Baroille P; Flesch M; Fargeot P; Coudert B; Mayer F; Fumoleau P; Chauffert B
    Anticancer Drugs; 2006 Nov; 17(10):1211-7. PubMed ID: 17075321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Evaluation of CDDP administration into the body cavity].
    Kikuchi K; Fujisaki M; Tamura T; Takahashi R; Kurihara E; Takada Y; Suito T; Uematsu Y
    Gan To Kagaku Ryoho; 1987 Dec; 14(12):3253-8. PubMed ID: 3688890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experimental and clinical evaluation of cisplatin-containing microspheres as intraperitoneal chemotherapy for ovarian cancer.
    Sugiyama T; Kumagai S; Nishida T; Ushijima K; Matsuo T; Yakushiji M; Hyon SH; Ikada Y
    Anticancer Res; 1998; 18(4B):2837-42. PubMed ID: 9713471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pharmacokinetics following intraperitoneal sequential administration of cisplatin and fluorouracil for gastric cancer].
    Hiratsuka M; Furukawa H; Iwanaga T; Nakamori S; Masutani S; Ohigashi H; Kameyama M; Sasaki Y; Kabuto T; Ishikawa O
    Gan To Kagaku Ryoho; 1993 Aug; 20(11):1627-30. PubMed ID: 8373234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of cisplatin as intraoperative hyperthermic peritoneal lavage (IHPL) in patients with locally advanced gastric cancer: analysis of pharmacokinetics and of nephrotoxicity.
    Kern W; Braess J; Kotschofsky M; Samel S; Becker H; Hiddemann W; Schleyer E
    Anticancer Res; 2002; 22(5):3099-102. PubMed ID: 12530050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.